New treatment tested for rare blood disorder in china
NCT ID NCT05876351
Summary
This study tested whether the drug eculizumab can help control atypical hemolytic uremic syndrome (aHUS), a rare blood disorder that can damage kidneys. The trial included 25 Chinese children and adults who hadn't previously tried similar complement inhibitor treatments. Participants received the drug for 26 weeks while researchers monitored their blood counts, kidney function, and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100045, China
-
Research Site
Changsha, 410007, China
-
Research Site
Qingdao, 110016, China
-
Research Site
Taiyuan, 030012, China
-
Research Site
Wuhan, 430030, China
Conditions
Explore the condition pages connected to this study.